Conference Coverage

Adalimumab strikes out for aortic inflammation in psoriasis

Publish date: June 27, 2018

 

REPORTING FROM IID 2018

The work was funded by the National Institutes of Health and AbbVie, adalimumab’s maker. Among many industry ties, Dr. Gelfand is a consultant for Janssen, maker of ustekinumab, and receives research grants from Janssen and AbbVie.

SOURCE: Gelfand JM et al. IID 2018, Abstract 393.

Pages

Recommended Reading

FDA approves IL-23 antagonist for plaque psoriasis
Psoriatic Arthritis Resource Center
FDA approves certolizumab label update for pregnancy, breastfeeding
Psoriatic Arthritis Resource Center
Study using U.K. data quantifies infection risk associated with psoriasis
Psoriatic Arthritis Resource Center
AbbVie, Samsung Bioepis settle suits with delayed U.S. entry for adalimumab biosimilar
Psoriatic Arthritis Resource Center
New PsA questionnaire fails to beat existing early screening methods
Psoriatic Arthritis Resource Center
How to avoid severe diarrhea from apremilast
Psoriatic Arthritis Resource Center
Is PASI 100 the new benchmark in psoriasis?
Psoriatic Arthritis Resource Center
Psoriasis duration reflects cardiovascular event risk
Psoriatic Arthritis Resource Center
CBC values linked to CVD risk in psoriasis
Psoriatic Arthritis Resource Center
Psoriasis therapy with biologics not linked to increased cancer risk
Psoriatic Arthritis Resource Center